Clinical trials: Brittle Bone Disorders
Osteogenesis Imperfecta
Boost Brittle Bones Before Birth
An exploratory, open label, multiple dose, multicentre phase I/II trial evaluating safety and efficacy of postnatal or prenatal and postnatal administration of allogeneic expanded fetal mesenchymal stem cells for the treatment of…
- Trial name
- BOOSTB4 (NCT03706482)
- Testing
- BOOST cells
- Where
- Sweden
- Volunteers
- 18 people
- Sponsor
- Karolinska Institutet
Osteogenesis Imperfecta, Brittle Bone Disorders
Osteogenesis Imperfecta (OI) Quality of Life Survey Pilot Project 2
The purpose of this study is to explore the patient perspective of disease burden in Osteogenesis Imperfecta (OI). Participants will complete a web-based survey of questions which are usually administered within the…
- Trial name
- NCT02793063
- Testing
- Web-based Survey
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of South Florida
Osteogenesis Imperfecta
BBD Longitudinal Study of Osteogenesis Imperfecta
Osteogenesis Imperfecta (OI) is a rare disorder of increased bone fragility characterized by fractures with minimal or absent trauma, dentinogenesis imperfecta (DI), and, in adult years, hearing loss.
- Trial name
- NCT02432625
- Where
- 12 sites in United States, Canada
- Volunteers
- 1,000 people
- Sponsor
- Baylor College of Medicine
Osteogenesis Imperfecta
Zoledronic Acid in Children (1 -17 Years) With Severe Osteogenesis Imperfecta
This is an extension study to examine the long-term safety and efficacy of zoledronic acid in patients who have completed the core CZOL446H2202 study.
- Trial name
- NCT00131118
- Testing
- Zoledronic Acid
- Where
- 10 sites in United States
- Volunteers
- 127 people
- Sponsor
- Novartis Pharmaceuticals
Osteogenesis Imperfecta
Post-market Observational Study on JTIN Telescopic Nail in Osteogenesis Imperfecta Pediatric Patients
This study has been planned as part of the Orthofix Srl post-market active surveillance plan for the collection of data on both the clinical performance and the safety profile of the JTIN.
- Trial name
- JTIN (NCT05612139)
- Testing
- JTIN implantation surgery
- Where
- France
- Volunteers
- 14 people
- Sponsor
- Orthofix s.r.l.
Osteogenesis Imperfecta
Boost to Brittle Bones - Stem Cell Transplantation for Treatment of Brittle Bones
An exploratory, open label, multiple dose, phase I/II trial (n=15) evaluating safety and efficacy of intravenous and intraosseous infusion of allogeneic expanded fetal mesenchymal stem cells (MSC) for the treatment of severe…
- Trial name
- BOOST2B (NCT04623606)
- Testing
- BOOST cells
- Where
- India
- Volunteers
- 15 people
- Sponsor
- Christian Medical College, Vellore, India
Osteogenesis Imperfecta
Effects of Bisphosphonates on OI-Related Hearing Loss
Osteogenesis Imperfecta-related hearing loss usually occurs in individuals with mild (type I) OI and is much earlier in onset than age-related hearing loss, with the majority of individuals experiencing some minor hearing loss in…
- Trial name
- NCT04152551
- Testing
- Risedronate Oral Tablet
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Hospital for Special Surgery, New York
Osteogenesis Imperfecta
Bisphosphonate Treatment of Osteogenesis Imperfecta
The primary purpose of this trial is to evaluate whether the investigational medication is safe, effective and has the ability to increase spine bone density in osteogenesis imperfecta (OI) patients.
- Trial name
- NCT00063479
- Testing
- Zoledronic Acid
- Where
- 10 sites in United States
- Volunteers
- 158 people
- Sponsor
- Novartis Pharmaceuticals
Osteogenesis Imperfecta, Brittle Bone Disorders
Pregnancy in Osteogenesis Imperfecta (OI) Registry
The purpose of this study is to learn about pregnancy outcomes in osteogenesis imperfecta (OI). Patients enrolled in the Brittle Bone Disorders (BBD) Contact Registry (CR) will be invited via email to participate in this study.
- Trial name
- NCT03072303
- Testing
- Web-based Survey
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- University of South Florida
Osteogenesis Imperfecta
Evaluation and Intervention for the Effects of Osteogenesis Imperfecta
We propose a longitudinal study of the natural history of types III and IV osteogenesis imperfecta for children age birth to 25 years.
- Trial name
- NCT00001594
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Brittle Bone Disease
Preventive Fixation of Lower Limbs in Osteogenesis Imperfecta (Brittle Bone Disease) With the Highlight of the Fassier-Duval
Osteogenesis imperfecta (or brittle bone disease) is a rare genetic disease characterized by fragile bone and a low mass ossue, secondary to abnormal collagen synthesis. This is a real congenital osteoporosis.
- Trial name
- Fassier-Duval (NCT02868294)
- Testing
- Fassier-Duval Nail
- Where
- France
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille